Phase 1 trial of TSR-022 in combination with an anti-PD-1 antibody, TSR-042, in solid tumour patients
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs TSR 022 (Primary) ; TSR 042 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Aug 2017 According to a TESARO media release, Status changed from planning to recruiting.
- 09 Mar 2017 New trial record
- 28 Feb 2017 According to a TESARO media release, this trial will initiate in mid-2017.